Speech-Language Pathologists in Mesa, AZ Accepting Medicare

362 Speech-Language Pathologists found. Showing 121 - 140

Charlotte Torma Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 630 N Hunt Dr, Mesa, AZ 85203 Phone: 480-472-7500

Mackenzie Greer, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 551 S Higley Rd, Mesa, AZ 85206 Phone: 623-334-5299

Mrs. Judith Lynne Perkins, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1025 N Country Club Dr, Mesa, AZ 85201 Phone: 480-472-0727    Fax: 480-472-0705

Miss Natalie Jo Meier, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1025 N Country Club Dr, Mesa, AZ 85201 Phone: 480-472-0727

Christine Forti Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1025 N Country Club Dr, Mesa, AZ 85201 Phone: 480-472-7200

Melissa Hurst, CCC-SLP Speech-Language Pathologist Medicare: Accepting Medicare Assignments Practice Location: 6840 E Brown Rd Ste 104, Mesa, AZ 85207 Phone: 480-719-8080    Fax: 480-981-8595

Amber Shelton, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 4925 E Ingram St, Mesa, AZ 85205 Phone: 480-472-8500

Diane Olsen, SPT Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2414 N Trenton, Mesa, AZ 85207 Phone: 480-380-2810    Fax: 480-380-2861

Lori Littlefield, MS,CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 551 S Higley Rd, Mesa, AZ 85206 Phone: 480-892-9777    Fax: 480-635-0222

Jennifer K. Pena Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1025 N Country Club Dr, Mesa, AZ 85201 Phone: 480-472-0727    Fax: 480-472-0705

Ms. Kim Lauren Snow, MA Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 945 W 8th St, Mesa, AZ 85201 Phone: 480-472-4414

Stacy Fusco, MS,CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 551 S Higley Rd, Mesa, AZ 85206 Phone: 480-892-9777    Fax: 480-635-0222

Meredith Lynn Ross Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1025 N Country Club Dr, Mesa, AZ 85201 Phone: 480-472-0502    Fax: 048-472-0502

Dba Angela Fox Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2834 S Extension Rd, Unit 1087, Mesa, AZ 85210 Phone: 480-773-1282

Jamie Lynn Petersen Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 1400 S Dobson Rd, Mesa, AZ 85202 Phone: 480-412-7724

Brett Ellis Martin, M.S. Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2150 S Country Club Dr Ste 20, Mesa, AZ 85210 Phone: 480-398-4280    Fax: 480-398-4281

Brittney Blau Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 551 S Higley Rd, Mesa, AZ 85206 Phone: 480-892-9777

Mrs. Christine Denise Brooks, MS COMM DISORDERS NS Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 4542 E Inverness Ave Ste 210, Mesa, AZ 85206 Phone: 480-540-4183

Lisa Kathman, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1025 N Country Club Dr, Mesa, AZ 85201 Phone: 480-472-0727    Fax: 480-472-0705

Ms. Judith Ann Baldwin, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 9435 E Lynwood St, Mesa, AZ 85207 Phone: 480-380-2851

News Archive

‘Risky' view of thrombolysis in subtherapeutic warfarin patients disputed

A study in JAMA challenges the view that intravenous thrombolysis is a particularly risky procedure in stroke patients with subtherapeutic international normalized ratios.

Phase 3 study of INLYTA fails to meet primary endpoint in treatment-naïve patients with RCC

Pfizer Inc. announced today that a Phase 3 study of INLYTA (axitinib) did not meet its primary endpoint of demonstrating statistically significantly longer progression-free survival, versus sorafenib, in treatment-naïve patients with advanced renal cell carcinoma.

Incyte announces Phase 2 FIGHT-202 trial data in patients with cholangiocarcinoma

Incyte Corporation announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment.

Pharmacyclics wins 2014 Society for Medicines Research Award for Drug Discovery

Pharmacyclics, Inc. today announced that it has won the prestigious 2014 Society for Medicines Research Award for Drug Discovery for its discovery of ibrutinib (IMBRUVICA). The award was presented by The Society of Medicines Research at its biennial award lecture in Kensington, London.

UTHSC researchers awarded $1.9 million to study white matter mechanisms underlying dementia

The National Institute of Neurological Disorders and Stroke has awarded two UTHSC researchers over $1.9 million to study the pathogenesis of white matter damage, a main contributing factor to dementia.

Read more Medical News

› Verified 4 days ago

• «
• 2
• 3
• 4
• 5
• 6
• 7(current)
• 8
• 9
• 10
• 11
• 12
• »